Skip to main content

Advertisement

Table 4 Prevention of amyloid accumulation and microglial activation by SAR255952 and its human homolog SAR228810 in immunotolerized and non-immunotolerized APPSL transgenic mice

From: SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

  Treatment groups No. of animals Mean value ± SEM Effect size p value
Amyloid β immunohistochemistry total area cortex (μm2)
 Non-immunotolerized Ctrl-IgG1 8 696,471 81,813   
 Immunotolerized Ctrl-IgG1 9 569,092 63,738 −18% vs non-immunotolerized NS
 Immunotolerized SAR228810 8 207,996 27,252 −63% vs immunotolerized DM4 < 0.001
 Immunotolerized SAR255952 8 197,600 17,064 −65% vs immunotolerized DM4 < 0.001
Cystatin F mRNA hippocampus (related units)
 Non-immunotolerized Ctrl-IgG1 12 78 7.5   
 Immunotolerized Ctrl-IgG1 12 80 8.9 + 3% vs non-immunotolerized NS
 Immunotolerized SAR228810 12 24 3.2 −70% vs immunotolerized DM4 < 0.001
 Immunotolerized SAR255952 9 28 2.8 −66% vs immunotolerized DM4 < 0.001
  1. All animals were treated with the same dose (10 mg/kg) of the indicated antibodies
  2. NS not significant, SEM standard error of the mean